Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005094 · ClinicalTrials.gov registry record · Phase 3
Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,170
- Enrollment target
NCT00005094: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00005094 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,170 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005094, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,170 participants
- Enrollment target
Study Summary
Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib has been approved for use in reducing the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP). It is not known whether there is a clinical benefit from a reduction in the number of colorectal polyps in FAP patients. The use of celecoxib may be an effective way to prevent the development of sporadic adenomatous polyps, precursors of colorectal cancer. This randomized phase III trial is studying celecoxib to see how well it works compared to a placebo in preventing the development of adenomatous colorectal polyps in patients who have had at least one polyp removed.
Interventions
- OTHER placebo
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,170 participants |
| Start Date | 2000-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005094
The ClinicalTrials.gov registry entry for NCT00005094 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00005094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005094 about?
NCT00005094 is a clinical study titled "Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps". Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib has been approved for use in reducing the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP). It is not known whether there is a clinical benefit from a ...
What is the current status of trial NCT00005094?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,170 participants. The study started on 2000-03.
What interventions are being tested in trial NCT00005094?
The interventions under investigation include: placebo (OTHER), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00005094?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.